Published in Clin Cancer Res on August 15, 2006
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol (2007) 3.21
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest (2007) 2.78
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Delivery of siRNA therapeutics: barriers and carriers. AAPS J (2010) 2.15
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res (2011) 2.03
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res (2009) 1.73
Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets (2011) 1.65
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res (2009) 1.61
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem (2010) 1.58
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res (2008) 1.55
Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res (2008) 1.51
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia (2011) 1.42
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2009) 1.37
Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res (2010) 1.34
Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev (2010) 1.32
Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer (2010) 1.30
Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther (2009) 1.30
The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther (2010) 1.22
Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis (2012) 1.20
Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer (2009) 1.18
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One (2011) 1.18
Selective gene silencing by viral delivery of short hairpin RNA. Virol J (2010) 1.17
Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res (2011) 1.14
Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther (2012) 1.13
Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine (2011) 1.13
The dicey role of Dicer: implications for RNAi therapy. Cancer Res (2010) 1.13
Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev (2013) 1.12
Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J Med Chem (2009) 1.11
Polymers in small-interfering RNA delivery. Nucleic Acid Ther (2011) 1.09
Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res (2012) 1.08
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst (2011) 1.08
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res (2012) 1.05
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res (2008) 1.04
Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res (2011) 1.03
Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther (2010) 1.02
Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev (2015) 1.01
Changes in gene expression and cellular architecture in an ovarian cancer progression model. PLoS One (2011) 1.01
Novel strategies for reversing platinum resistance. Drug Resist Updat (2009) 1.00
Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol (2009) 0.98
MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells. Anticancer Agents Med Chem (2014) 0.97
c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res (2009) 0.97
Evaluation of specific delivery of chimeric phi29 pRNA/siRNA nanoparticles to multiple tumor cells. Mol Biosyst (2009) 0.96
EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res (2010) 0.95
Vectoring siRNA therapeutics into the clinic. Nat Rev Clin Oncol (2010) 0.94
Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res (2011) 0.93
Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol (2007) 0.93
Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther (2014) 0.92
Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int (2013) 0.92
Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res (2014) 0.92
Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res (2009) 0.90
EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis (2013) 0.90
Hormonal regulation and distinct functions of semaphorin-3B and semaphorin-3F in ovarian cancer. Mol Cancer Ther (2010) 0.89
Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors. J Pharm Innov (2014) 0.89
The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target. Oncotarget (2011) 0.87
Advances in Systemic siRNA Delivery. Drugs Future (2009) 0.87
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther (2014) 0.87
Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv (2008) 0.86
Neutral polymeric micelles for RNA delivery. Bioconjug Chem (2013) 0.86
Nanofiber-mediated inhibition of focal adhesion kinase sensitizes glioma stemlike cells to epidermal growth factor receptor inhibition. Neuro Oncol (2013) 0.85
Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines. PLoS One (2014) 0.85
Targeted delivery of siRNA into breast cancer cells via phage fusion proteins. Mol Pharm (2013) 0.85
Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett (2012) 0.85
FAK deletion promotes p53-mediated induction of p21, DNA-damage responses and radio-resistance in advanced squamous cancer cells. PLoS One (2011) 0.85
Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol (2013) 0.84
Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev (2016) 0.82
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des (2012) 0.81
Tissue Transglutaminase (TG2)-Induced Inflammation in Initiation, Progression, and Pathogenesis of Pancreatic Cancer. Cancers (Basel) (2011) 0.80
Inhibition of ICAM2 induces radiosensitization in oral squamous cell carcinoma cells. Br J Cancer (2008) 0.80
Formulation Strategies, Characterization, and In Vitro Evaluation of Lecithin-Based Nanoparticles for siRNA Delivery. J Drug Deliv (2012) 0.80
Effect of surface properties on liposomal siRNA delivery. Biomaterials (2015) 0.80
The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun (2015) 0.79
Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res (2015) 0.79
Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am (2012) 0.79
New aspects of gene-silencing for the treatment of cardiovascular diseases. Pharmaceuticals (Basel) (2013) 0.77
Multifunctional nanoparticles for cancer immunotherapy. Hum Vaccin Immunother (2016) 0.76
ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell (2016) 0.76
siRNA Delivery by Stimuli-Sensitive Nanocarriers. Curr Pharm Des (2015) 0.76
A terrible beauty: a physician's story of ovarian cancer. Can Fam Physician (2007) 0.75
Suppression of human MDA-MB-435S tumor by U6 promoter-driven short hairpin RNAs targeting focal adhesion kinase. J Cancer Res Clin Oncol (2010) 0.75
Engineering of monobody conjugates for human EphA2-specific optical imaging. PLoS One (2017) 0.75
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol (2005) 11.74
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Unlocking the potential of the human genome with RNA interference. Nature (2004) 6.70
FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol (2000) 6.54
RNA interference in adult mice. Nature (2002) 5.33
Signaling through focal adhesion kinase. Prog Biophys Mol Biol (1999) 5.33
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res (1995) 3.38
Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol (2003) 3.27
Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta (2001) 3.25
Differential regulation of cell motility and invasion by FAK. J Cell Biol (2003) 3.15
Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res (2000) 3.03
Integrin signalling and tyrosine phosphorylation: just the FAKs? Trends Cell Biol (1998) 2.83
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res (2003) 2.32
Molecular determinants of ovarian cancer plasticity. Am J Pathol (2001) 2.32
Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol (2004) 2.12
Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer (1999) 1.74
Focal adhesion kinase: an integrin-linked protein tyrosine kinase. Trends Cell Biol (1993) 1.70
Complex formation with focal adhesion kinase: A mechanism to regulate activity and subcellular localization of Src kinases. Mol Biol Cell (1999) 1.67
CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene (2004) 1.66
Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene (2002) 1.65
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res (2005) 1.63
Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor. J Natl Cancer Inst (2000) 1.62
Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem (2000) 1.59
Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res (2000) 1.57
Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res (2005) 1.47
RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun (2003) 1.47
Both focal adhesion kinase and c-Ras are required for the enhanced matrix metalloproteinase 9 secretion by fibronectin in ovarian cancer cells. Cancer Res (1998) 1.33
Focal adhesion kinase as a potential target in oncology. Expert Opin Pharmacother (2003) 1.28
Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res (2002) 1.26
CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase. Int J Cancer (2002) 1.26
Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer (2004) 1.21
A role for FAK in the Concanavalin A-dependent secretion of matrix metalloproteinase-2 and -9. Oncogene (2000) 1.12
Insulin-like growth factor I stimulates tyrosine phosphorylation of p130(Cas), focal adhesion kinase, and paxillin. Role of phosphatidylinositol 3'-kinase and formation of a p130(Cas).Crk complex. J Biol Chem (1998) 1.08
The focal adhesion kinase. J Endocrinol (1996) 1.07
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol (2001) 1.07
Focal adhesion kinase expression in oral cancers. Head Neck (1998) 1.04
Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett (1997) 1.03
Liposomes modified with cyclic RGD peptide for tumor targeting. J Drug Target (2004) 1.03
Therapeutic potential of retroviral RNAi vectors. Expert Opin Biol Ther (2004) 1.00
Focal adhesion kinase overexpression induces enhanced pathological retinal angiogenesis. Invest Ophthalmol Vis Sci (2004) 0.93
The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002. Clin Cancer Res (2002) 0.91
Overexpression of focal adhesion kinase (p125FAK) in human colorectal carcinoma liver metastases: independence from c-src or c-yes activation. Ann Surg Oncol (1997) 0.90
First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. J Clin Oncol (1999) 0.87
Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J Pharmacol Exp Ther (1999) 0.87
Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. J Clin Oncol (2003) 0.83
Gene therapy approaches to HIV infection. Am J Pharmacogenomics (2002) 0.81
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Ovarian cancer. Lancet (2009) 3.95
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res (2006) 3.58
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol (2004) 3.49
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36
Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol (2007) 3.13
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
A functional genomic perspective on human well-being. Proc Natl Acad Sci U S A (2013) 2.98
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Reciprocal regulation of the neural and innate immune systems. Nat Rev Immunol (2011) 2.87
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy (2010) 2.62
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol (2013) 2.47
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res (2006) 2.32
Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A (2010) 2.31
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol (2005) 2.17
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol (2012) 2.14
Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol (2004) 2.12
Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol (2006) 2.07
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04